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No drug can be approved for general use by physicians inthe 
United States unless it has been shown to be clinically 
be&&l for putients and its properties have been su& 
ciently well characterized that appropriate instnuGons cau 
be written to guide its use. How can we determine whether 
a w is clinically beneficial? To be of value, a drug must 
permitpatientswithadiseaseeithertofeelbetterortolive 
louger,orboth.Ifadrugdoesnotlessensymptomsorp&ng 
lifk,therewouldbelittlesupport~its~byaregula- 
unyagencyandlittlereasonMtsclinklusebyphysicians. 
Demonstratingthatadrugisclinicallybeneficialforthe 
treatment of heart failure is a challenging task. Symptoms 
are hiiy subjective and are di&ult to characterize and 
quantify, and the cvaltion of the e&t of a drug on 
survivalrequiresacontrolledtrialoflongduratkmiualarge 
numberofpatients.Becauseofthedi8k&esi&rentinthe 
assessment of both quality and quantity oflik, k%&@ors 
aud mutical wmpanies have proposed using alter- 
uatemeasmesofe&acy(namely,surrogsteendpoiuts)tbat 
arebelieved to be closely ass&a&d with symptoms or 
survivalbutarenotdh-ectmeasuresofclinklbene6t.The 
adoption of such surrogate end points would dramatMy 
facilitate the evaluation of new drugs, but we should ask 
CausurrogateendpuintsbeusedtodisGnguishektive 
&omineitktivedrugs?Wouldtheuseofsurro@eend 
pointsprovidereliileinformationabout theeffectofadrua 
011 symptoms orsurvival? 
TheComceptafS~lEQd~ 
A physiologic variable iscommonly H as a smx~ 
gateendpointwbenthevariablemeetstwobasic~~ 
First,thereexistsastafistku~relatkmbetweenthe~ 
su~~endpointandacliuicaloutcome.Forexampka 
variety ofphysiolo#c variables have been showu to predict 
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death in patients withbrtihihue, inchlding ejection fmc- 
tion, ventridar arrhythmias ud phtsma norepiuephrine (1). 
Second, there xists apathophy&dog& basis far believing 
thatthesmogateeudpointisthepfimarydetemkantofthe 
outcamedthe*F~example,Wal.e~to 
believethatapmgressivedecmaseiuqjectkmfraction 
mults in death due to p@ve heart frrilure, ventricular 
arrhythmiasleadtosuddendeathaud&cuMu#levelsof 
. 
#weplaephrineC8Udirectlyiqjuntheheart.The6UdiOgthat 
a sttoruj asso&tion exists between a variable and an 
outcome-both statistically and pathophysiologically- 
commonlyleadsphysicianstoproposethatthemeasluement 
d~evarieblebewedinsteadd(apasurro%stefor)the 
dhectmeasuleofclinicaloutcome. 
Theuseofsmrogateendpohrtsisnotonlyadvocatedin 
the development of drugs, but is commonplace in the mar- 
hetinq of drugs used in clinical practice. Specitlcatly, physi- 
ciansareoftenenwursqedtoprescribeonedrugforheart 
faihueoveranotheronthebasisofthedilkrenceinthe 
etkts exerted by the two druqs on a physiologic variable. 
For example, inthe absence ofany survival data. physicians 
mi#tselectonepositiveiwtropicdrugoveranotherifit 
wereknownthatthetwodrugsdikmdintheiretfectson 
. 
tentndnarrhythmias. However, such adecision assumes 
thatventriculararrhythmiasareavalidsuwogateendpoint 
for survival (that is, the druq with superior e&ts on 
ventricular arrhythmias has superior effects w survival). 
inessence,theeRectofadrugonsurro@eendpoints 
provides u with impressions data-about the possible 
e&t of a m on clinical events. Such impressions arethe 
bases of hypotheses that can be tested in controlled clinical 
trials that directly measure the clinical benefits oftherapeu- 
tic interventions. 
LlmitawaufsumDgateEndPoints 
The results of recent cliical trials have considerably 
WG&?llGd~feithhthCreliabilityandvalidityOfSurrogate 
endpointSinthcevaluationof~formfailun.Many 
yem m, physrcians believed that ventricuIar premature 
beatswereavalidsurrQtateendpointfiwsurvivalandthus 
WMpCtCddlUgSthatSUpgrressedVClltliC~~ 
beat!3 to pdoq lifb. However, the mults of the cardii 
Adythiasuppression~(cAsT)(2)demonstratedthat 
asympton&ventricularpnmaturebeatscouldnotbe 
considered a valid surrogate end point because the incidence 
ofdeathwasw-bydrugsthatre- 
duced the frequency and complexity ofthese rhythm distur- 
bances. Similarly, many ears ago, physicians believed that 
. 
mtmularGmctiouwasa’validsurro#eeadpointfor 
survival inpatients with c@aic heart failure aud thus we 
expWteddrug!3thatenhaGdveutriadarfunctiwtopro- 
longlikHowever,theRaspcctiveRam&&ed~e 
Survival Evaluation (PROMISE) (3) showed us that the 
kidenceddeathcouldbeincrear&by~thataug- 
meatcdcardiaccontractil~~luadimprpvedventriclll~func- 
tion. The results of these two trials (2.3) raised concerns 
about the validity of all suwogate end points used to evaluate 
audumuculardNgs. 
How can we explain the ditliculties ncountered in the 
use of surrogate end points in the evaluation f new drugs? 
There are at least wo possibilities. First, the observation 
that an end point (measured at one point in time) is statis 
tally associated with an outcome does not mean that he end 
point is pathophysioloqically related to the outcome. We 
would be able to support the existence ofa pathophysiologic 
relatioaifwewulddetermiPethatac~inthephysio_ 
logic variable (produced byan intervention) invariably pre- 
dicted a change in cliical outcome. The evidence for a 
pathophysiologic relatii would be extremely strong if the 
change inthe end point were quantitatively associakd with 
the change inthe survival (that is, for every unit change in
the end point, there was a predictable unit change inthe 
outcome). Unfortunately, this criterion cannot be met for 
any of the surrogak end points that have been proposed 
for use in the evaluation f drugs for heart failure. 
Second, even if a qua&&e relation can be established 
between a suwogate end point and a clinical outcome. 
chaqges in a surrogag end point may provide misleading 
information about the etfects of a drug on survival ifthe new 
h has au additional property (independent of itseffects on 
the surrogate end point) that may affect survival ina direc- 
tionoppositetothatpredictedbytheeffectofthedrugonthe 
sunugate end point. For example, if we believe that he 
lowering ofthe serum cholesterol level is a valid sunogate 
end point, a new drug that reduces the cholesterol level 
would be expected toreduce coronary events. However, 
this might not prove to be the case if, in addition toits effects 
on serum cholesterol, the new drug acted on the blood to 
pmduce a hypemagulable state. To make matters more 
complicated, themagnitude of these two opposing elfects 
maydepeudonthedoseofthedrugadmiWered.For 
example, the new drug may lower serum cholesterol in 
pmportion to the dose admiuistered, butmay adversely 
a$iectbloodc~~onlyathigh&ses.Ifso,lowdoses 
ofthedmgmayreducethemomlityrate,whereashigh 
dosesmayadverselyaktsurvival. Suchacomplexrelation 
between dose and sumival could not have been discerned by
simp1yrelyineonmeasurementsofthee&ctofthedrugon 
serum cholesterol. Consequently, if serum cholesterol were 
us dasasumgateeadpointtoapprovethedrugaudguide 
its therapeutic use, many physicians would utilize hi@ doses 
of the drqg to achieve maximal effects 09 semm cholesterol 
without recognidng that SucC ‘oses actually increased the 
mart&y rate of treated patienti. 
whatEndpaintsArecllnicallyRelevantin 
the Treatment of Heart Failure? 
Fromthepreced&discussion,itseemsclexthattrials 
shouldbedesignedtoevaluatethee&ctdanewdrugou 
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clinica!ly relevant rather than surrogate end points. Such a 
conclusion should not be construed tosuggest that valid 
sunogate end points will be impossible to develop in the 
future. Yet, in the area of heart failure, no surrogate end 
point currently exists that can substitute for the direct 
assessment of adrug on symptoms or survival ideally in the 
context of a placebo-controlled trial.
Amemment ofsymptutns. The most direct approach to the 
evaluation f heart failure is to inquire about symptoms of 
dyspnea and fatigue. However, these symptoms are dithcult 
tu evaluate and their severity is impossible to quantify 
without relating them to specific activities. As physicians, 
we do not ask patients with heart failure if they experience 
shortness of breath because allpatients with heart failure (as 
well as normal individuals) experience this symptom with 
strenuous exercise. Instead, we ask patients about how 
much they can do and what activities they can perform until 
dyspnea is experienced. Viewed in this hshion, the evahra- 
tion of the severity of the symptoms of heart failure cannot 
be separated from the assessment of the disability produced 
by the symptoms. Therapy isintended to reduce the severity 
of symptoms and thereby enhance the ability of the patient 
to perform activities ofdaily living that would otherwise b  
limited by the symptoms of heart Khue. Hence, au increase 
in functional capacity isan expected outcome ofany treat- 
ment intended tolessen the symptoms of heart failure and, 
thus, the direct assessment of functional capacity represents 
a clinically relevant end point-not a suuogate end point-in 
the evaluation f new drugs for heart tihue. 
How can we assess Cmctional capacity inthe context of 
a clinical trial? Traditionally, symptoms are class&d ac- 
cording to a categoric s ale, such as that of the New York 
Heart Association, and the ethcacy of a therapeutic inter- 
vention is judged using each patient as his or her own 
control. Although simple, such a classification is not quan- 
tiiiable, is sub@ to considerable interobserver a iability 
and lacks adequate s nsitivity to detect important changes in 
functional capacity. Furthermore, the condition of many 
patients seeing a physician orreceiving a drup for the fust 
time improves (in part) because they have ntered a new 
therapeutic environment, which (by increasing the expecta- 
tion of anticipated bet&) reduces anxiety concerning 
symptoms and t&forces compliice with recommendations 
concerning treatment. The creation of such a therapeutic 
eovitonment occurs commonly inclinical practice, but is 
greatly exaggerated in the settinp ofa formal research trial in 
which the personal ttention provided tothe patient teaches 
extreme l vels. Such attention may explain why 20% to 40% 
of patients who enter heart failure trials show significant 
improvement with placebo therapy (4). Even when acontrol 
goup is available for comparison, the evahration f sump 
toms by means of the New York Heart Assuciation classili- 
cation remains a hiphly sul&ctive matter that is greatly 
Muencedbytheunderlyingbiasesofbuththepatientand 
the physician. 
AsserJsmmt of fIutd&d capacity. Given these diicul- 
ties, a variety of objective and quantitative m asurements of 
functional capacity have been developed in recent years, 
inChIding several quality-of-life instruments and many differ- 
ent exercise tolerance t sts. However, no single quality-of- 
lie instrument or exercise tolerance t st is universally useful 
fortheevahmtionofalldrugsforthetreatmentafheart 
failure. The efficacy of certain ~IIIJPJ may be ideally exam- 
ined by the use of submaximal rather than maximal exercise 
tests (5); other therapies may require specializxl question- 
naires that focus on specific activities. Yet, amonp all of the 
assessments used to evahukte the functional capacity of 
patients with heart failure, the exercise tolerance t st has a 
special place in drug development. Thefindii that a drug 
has improved a patient’s performance on an exercise t st 
provides reassurance that the amelioration of symptoms 
produced bytreatment has actually enhanced the patient’s 
ability to perform daily activities. This rules out the possi- 
bility that a drup could reduce the symptoms of heart faihrre 
not by lessening heart failure but by producing other symp 
toms that might limit exercise. For example, a drug that 
produces arthritis n the lower limbs would greatly reduce 
the symptoms of heart failure if the arthritis everely re- 
stricted the ability to exercise. Such an example might sound 
absurd; nonetheless, it demonstrates whyfunctional capac- 
ity must be e&rated in addition to symptoms in assessing 
the eflicacy of new drugs for heart failure. 
Experience with exercise t sting in a huge number of
placebo-controlled clinical trials ofdrugs for heart failure has 
generally shown that herapeutic interventions that lessen 
symptoms al o improve ffort olerance and, conversely, 
that symptomatically ine&ctive drugs pruduce little change 
in exercise capacity. Moreover, symptoms and exercise 
tolerance have been shown tu change ina parallel fashton as 
a function of dose, further support& the concept that 
changes in both symptoms and exercise tolerance t flect 
changes in the patient’s clinical status. However, it should 
benotedthatanimprovementinelfort&rancemaynotbe 
demonstrable in ach of the placebo-conbolled trials that 
may be wnducted with an eRective therapeutic agent. In 
fact. it is commonplace for a clinical development PWmm 
forausefuldrugtoincludeoneormorestudiesthatshow 
directionally favorable but noos@ftcaut changes in exer- 
cise tolerance in the patients receiving active therapy. The 
lack of statistical s- may uwur if investipators 
fail to incorporate specitic features into the desb uf the 
study that can minimize the incfease iu exercise tolerance in 
the patients reated with placebo (6). if the u&Ude of the 
therepeuticeffectis~orforotherreasons.Howe~er,~e 
researchprogramforane&ctivedNg~Y~~t 
idude trials in which, for the primary end point being 
evaluated, the etfect favors paMts treated with Placebo. 
Because ymptoms and exercise tolerance r present di-
rectmeasuresufpatientbene6tandcanbereadilY~sured 
iurigrrmuslydesignedstudies,th~would~~~~ 
reason to utiiixe or rely on any stmo@e end point for 
hrringWJStOftilCl~,phySiCiWSbelievedth~~erspeu- . . . ~~ilQpVCdlCftVeatricularfunction iLldbepFedild*y-inthe trwtmwtofc ronic 
~failme.onthebasisofthisbelief,inva6ivehemo= 
d~&adieswereviewedasacriti~carlystepinthe 
thec&ctsofthe~oncardiacoutpatand~~~ 
veatlicular lilling pressllles. If the hemodynsmic efftcts 
pmdacedbythedrugwerefavorable,adoseofthedrugwas 
selectedtoelicitthemastmakedhen@mamicekts 
without pmdkll# serious adverse &cts. If subseqlN!at 
studies showed that hese hemodynamic bene6ts we= sus- 
tainedduriag~termtreatmetlt,stievidencewasre 
gardedasanadeqllateIsurrogateendpoiattodemon~ 
theutilityofthedra#inthetEatmentofchroaicheart 
failure. 
Howmer,rUXlltstUdkShaveraiSedimporhrptcaneernS 
aboutthevaklitydhemodynamicmeawrementsasa 
surro#euuIpointforthe~ofadrugforthe 
katment of chlwlic heart failure. ControM Gals (3,7,8) 
aaVeshownthatdrUg!BthBtpl7MhKXStIikhlghWlUldynamic 
ben&sdonotnecesswilypMduceclhdcal~s.More- 
over,evenfixanekctiveagent,thedosethatproducesthe 
mostmakedhemodyasmic&ctsisaotaeces&lythe 
samedosethatprodueesthl!mostmarkedclinical~ts 
(9,lO). Because of these kliogs, there is 110 longer auy 
supportforthebeliefthathemodynamicvaIiablescaabe 
ased as a w end point for w etllcacy. Never- 
theless, an improvement in hemodynamic variables is still 
viewedasavalidbasisforapprovalofinbave~dnqgfiu 
thetrWmentof~cu&henrtfaik,althou&itisclearthat 
suchhemodyaamicdata&notrepnsenndirectevidenceof 
patient bendlt. 
Asimilarparadoxexistsf&anothercommoalyused 
m@UlKedthWWerityafheartfail~:periphereledema. 
SodiumrWntionisa&mcte&icdmost(butaotaU) 
puientswithheart~,and~ofedemais 
frequently (but not invaliRbly) acugWed by impM!!d 
cliaicatstatusandabsseniugofsymptoms.However,most 
dnrssthathavebeendeve@fxlforthe-tofheart 
fiilundllrhuJtheMdecadeproduceclhdcalbenefltswith- 
autaherhqgtheweightornuidbalanceofpatients.collse 
cluMtly,~thoueh~sinweigbtoredemam~ 
closely~m~~developmentprogramfwanynew 
~~4lewlmcvaIiablescannotbellsedasslnTo- 
tWeeWohts~thedficacy0f~tdrugs~heart 
failure. Nevertheless, it should be noted that chaages ia
weiebtaadedema~Stillvkwedasavalidbasis~r 
lrraauntdsuwlvaLEveniftherapydecreasesthe 
symptoms ofpatients wi hchronic heart ftiure, the mortal- 
ityrateiathesepatientsremainsextrem4yhigh.Hence,ia 
add&n to lessening symptoms, a therapeutic intervention 
maybeviewedasclinicaUyben&ialifthedrugrcducestk 
risk of death. In contra& to symptoms, the assessment of 
llUMtdi~iSObjective,quentifiableandWtSUbjeCttoOb 
-bias.~becauseSUKOg8~dpointsfor 
survivalarenotavahtde,theeEctofanytimapdc 
interventioaoamortalitycanbeassessedonlyinthecoatext 
ofarandomMplacebo-waWoUedtfialiaalargenumberof 
patieats. 
For~td~~tlSyeanr,mortalitywasviewedby 
physicians aad regulatory agencies solely in the context of 
pos~‘bletherapeutic~~yofadrug.~~cagents 
were primarily designed tolessen the symptoms of heart 
failun,ifstudiesshowedthattheseagentsalsoreducedthe 
risk of death, such iaformatioa would provide physicians 
withaaadditionalaadpowe&lreasontoprescrkthe~ 
In fad, the discovery that convm enzyme iahibitors 
exertedfavoraweeBctsaobothsymptomsandsurvivalhas 
beenthemqjorimpetasthathasledtothewid~ 
acceptanceofthesedrugsforthe~tofheart~are. 
However, da+ the last 5 years, evidence has m 
(fkomPR0MIsE[3]andothcrtIials)thatsomedNg!5that 
Ieduce the symptoms ofheart failure may adver!Iely Mu- 
encesurvival.This~hasshiftedourviewof 
morUystudiesiaadraWickhion;thatis,insteadd 
regardingmortalitytrialsasprovidingsuppkmentalinforma- 
tioa copcerpipg etlicacy, such studies are now seea as 
necessarytotheassessmentofthesaktyofaaewdrugfor 
the-tofheart!kilure.Suchsurvivaliaf6rmationmay 
beprov&dbythecoaductofasingie,buge4scale,well 
wntrolled study or by a meta4ysis of the mortality 
experienceofalargenumbezdpatientsenroUedinmany 
controued iflcacy trials. 
Survival stadies are expensive and time-coasuming; a 
sia@emortalitytrialearoll&severalthousandpatieatsmay 
costtensofmiUionsofdolbuumdnpuireyearstocomplete. 
As a result, here has been considerable intist in develop- 
* investi@ive approuhes that might address possible 
concemsaboutsurvivalbututilixefewerreso~s.Initiauy, 
invest@tors pmposed us@ a variety of physiol* end 
poiatsas~sfordeath,but(asoutlinedeaIlieriathis 
Eport)~areatpreselltnovalids~gateeadpointsfor 
mortality. More recently, investigators have wsted that 
theefkctofadrugoasurvivalmaybeadequate~yassessed 
by trials that focus on clinically relevant inWmed& end 
points(fkexample,hospitaktionforheartfake).There 
isaclearrationalefotthisapgnua&:becausehospitaka- 
tionSalEmOrecommWthandeath,trhllSfUcUSedOnmOr- 
bidityaresmallerandshorterthantrialsfocusedonmortal- 
ity. There is lie doubt that hospMktion represents an 
eveat ofclinicaI &orknce to the patient; thus, a chaagf2 ia 
i~kqueacyrel#esentsavalidmeasureoftheel6auzyofa 
newd~.However,itisnotclearthatchaagesinmorbidity 
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invariably paraIM changes in mortality in patients with heart 
failure; that is, drugs may reduce the frequency of hospital- 
ization but increase the mortality rate. As a result, trials 
evaluatiug cardiovascular morbidity cannot he used to ad- 
dress concerns that a new drug may adversely alfect survival 
in heart kihue. Nevertheless, thefrequency of hospitalixa- 
tion is a measure ofpatient be&t and remains an important 
secondary end point in mortality studies. 
BasisfbrtheApprovalofNewDrugs 
Because a muuber of variables and outcomes cau be 
measured in trials of new drugs for heart failure, it is 
appropriate to ash which end points are most important. 
Assuming that such end points can be identified, why 
measutw anything else? What purpose isserved by charac- 
Mixing the ekt of the dru8 on left ventricuhu f nction, 
neurohormonal systems, regional b ood tlow and other phys- 
iologic vmiables if such studies do not contribute in a 
SubstanMve way to the evahmtion f benefit or risk? In 
fact, on tbe basis ofrecent developments, some inves@tors 
and pharmaceutical sponsors might suggest an extreme 
approaciUbat the entire development prom should con- 
sist of a single survival study, which would evaluate both 
eikacyaudsalktyinalargenumberofpatientsoveralong 
period of time. Such an approach, t ey would argue, would 
spare the time aud expense involved inthe full evaluation f 
anewtherapeuticagentonlytofindaftermanyyearsof 
work that he agent incmases the mortality rate. Thus, why 
not evahmte mortahty first? Simply pick a dose that seems 
best and evahmte he effect of that dose on survival. If the 
study shows that he drug increases the mortality rate, it can 
be qu=Y aba&med;ifthestudyshowsthatthedrug 
reducesthemortalitymte,nootherstudiesareneeded 
becausethedrugisdes~forappnwel. 
We believe that the approach outlined iuthe previous 
paragmphdoesnotmpresentareasonableevahukmofa 
newtbempeuticagentaudthusdoesnotprovidethebasis 
forapproval.Tobe~letou~adnrg~thebenefitofa 
patieut,aphysicianneedsto muktandasmuchaboutthe 
agent as possible. How does the drug work? Fmquently, 
phammco&ticactionsidenti6edinthelabomtorybearlittle 
relation to the therapeutic elkcts identikd in a clinical trial. 
Howdoesthedlq@Iuencetheciinicalandphysioiogic 
features ofheart Mure (for example, l ft ventricular func- 
tion, neurohormonal systems, sodium balauce aud ventricu- 
lar arrhythmias)? Such information is commonly colkted 
by physicians during the routine -afthepatient 
withheartfaihrre,andphysiciansshouldunderstandhowa 
newdrugmighti&encethesefeatures.Asideknuits 
ability to prolong life, what other therapeutic value might the 
tqenthave?Dopatientstreatedwitbthedrugfeelbetteraud 
cautheydomore?Whatistheoptimaldoseofthedrug?Is 
thedosethatprolonuslifrEtheoPtimaIdoseofthedNg? 
he dose that produces optimal etkt~ on stiti ne~esm- 
ly the dose that produces optimal effects on s~rmptoms? 
No development program can adequately address ali of 
the questions that cau be raised about a new drys f0r the 
treatment of heart failure. Yet, a full development program 
should provide sufficient i fom&m qarding a variety of 
pharmaodogicandclinicalaspectsofthedrugtopermit 
physiciiandreg&orstoevahtatethe~~ 
reasonableness of thempeutic effect. No m ia ever eg 
provedonthebasisoftheresuhsofasinglestudy.DNgs~ 
approvedbyreguletoryagenciesandareprescribedby 
physicians because there exists a critical mass of data 
supportins their use. Most commonly, such critical mass i  
achievedwhentheresultsofatrial~~thedrugcaabe 
replicated and when such results make sense when viewed iu
the context of all of the iuformation available about the drug, 
Whentheavailabledatakadtoaco&tentpicture,itis 
easy to dehne the thempeutic role for a new agent. However, 
whendataamconlMugormissing,wesuspectthatsome- 
thing may be wrong and thus it may be masonable to suggest 
thatwedonotknowenoughaboutadrugtoahowits 
widespread use. 
What are the possible outcomes of a developmema! 
prwgramthathasfuUychanuM&theeRectofadrugon 
symptomsaudsurvival?Thereareatleastleastpossibih~ 
a dru  may 1) lessen symptoms and improve survival, 
2) worsen symptoms and survival, 3) lessen symptoms and 
worsen survival; and 4) worsen symptoms and improve 
survival. A decision qarding approvai is obvious for only 
two of these four outcomes. Speciklly, approval is ikely if 
the new drug relieved symptoms and prolonged life. whereas 
the new drug would be discarded if it worsened symptoms 
aad increased the risk ofdeath. However, judgments regard- 
iagapprovalcannotbeeasilyprediifortbeotherhvo 
outcomes. Wouldadrugbeapprovedifitreducedsymptoms 
audshorte&life?Wouldanewagentbeappnwedifit 
reducedthemortalityratebut~ symptoms?From 
our view, such mixed outcomes arenotkompatiilewitb 
approval,partkuhuiyifthemagniadeofthebelle6tis~ 
audthemagnitudeoftheriskissmaU.Forexample,adrug 
thatcompletelyaueviaUthesymptomsofheartthihlrein 
aUpatientswhoreceiveditbutkreasedthemorMitymte 
y1096couldneverthekssbeviewedasavahwble~finr 
thetreatmentofheartGhue.SimMy,adrugthatcom- 
pletelyekiuatedtheriskofdeathbutproducedamild 
womeuhrgofsymptomscouldstiUhavean&ortautthera- 
peutic role. Even if the examples were less extreme (that is, 
ifthemaguitudeoftheriskwassimilartothem@tudegf 
bellefit), many patients (after consuhation with their ph* 
cians)mightchoosetohetreatedwithanewdrug~d 
assumespecificrisksifthedesiredthempeutic~t~ 
importaut and could not be achieved in any other-y. h~ 
kt,suchdrugscouldhaveagreater~~~ 
petientswiththediseasethan~ntsthat~WeUtolerated 
butproduceonlysmalltherepeutic-.~iaSY~ 
patientswhosecondhhmproves~~~~ 
184A UPICKYANDPACKBR 
SURROOATB BND KMNTS IN HEART FAILURE 
therapy.Fkomthesecomments,itshouldbeappmatthat 
dmgsareappmvedonthebasisofanas8esmeatcftheir 
bendbviewedintbewntextd~~s. f3msequelltly,if 
eitherthehditsortheriskshavenoskeaclearlydehed 
duriDgthecomeofthedeveiopmeatofadmg,itwuuldbe 
diaacult tomake any reasoned decision re@iw its ap 
pnwal. 
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